Announcements
- PCI Biotech Holding ASA - Notice of Annual General Meeting 2024
- PCI Biotech Holding ASA - Annual Report 2023
- PCI Biotech second half 2023 interim results
- PCI Biotech: Invitation to second half interim 2023 results presentation
- PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing
- PCI Biotech: European patent for mRNA delivery with fimaNAc
- PCI Biotech: Employee share option scheme
- PCI Biotech: Write-down of share capital registered
- PCI Biotech first half 2023 interim results
- PCI Biotech: Invitation to first half interim 2023 results presentation
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 13.99 |
Average volume | -- |
---|---|
Shares outstanding | 37.33m |
Free float | 28.39m |
P/E (TTM) | -- |
Market cap | 59.65m NOK |
EPS (TTM) | -0.5443 NOK |
Data delayed at least 15 minutes, as of Jan 05 2022.
More ▼